Enhancing and developing DX services
First written in FY2023. 4 of 7 entries say "Restated". Latest entry: FY2026-H1.
1 other company's latest entry also says "Restated".
- FY2026-H1RestatedAnnual report
「Group-wide R&D expenses during the interim consolidated accounting period were ¥31,564 thousand, compared with ¥36,900 thousand in the same period of the previous year. There were no material changes in the status of the Group’s R&D activities during the interim consolidated accounting period.」
There were no material changes in R&D activities. R&D expenses during the interim consolidated accounting period were ¥31,564 thousand, down from ¥36,900 thousand in the same period of the previous year. - 2026-05-15AdvancedEarnings presentation
「Development projects progressed as planned and increased year on year.」
The company reported that DX revenue increased year on year as development projects progressed. - FY2025AdvancedAnnual report
「R&D activities during the consolidated fiscal year consisted primarily of developing DX services for businesses, and total R&D expenses were ¥73,935 thousand.」
The company continued R&D focused primarily on developing DX services for businesses, with R&D expenses of ¥73,935 thousand. - FY2025-H1RestatedAnnual report
「Group-wide R&D expenses during the interim consolidated accounting period were ¥36,900 thousand. There were no material changes in the status of the Group’s R&D activities during the interim consolidated accounting period.」
Although there were no material changes in R&D activities, Group-wide R&D expenses in the first half of 2025 were ¥36,900 thousand. - FY2024RestatedAnnual report
「To address these issues, we will develop and provide services that support the digitization of business processes overall and contribute to more sophisticated performance management and data utilization.」
The company stated its policy of continuously expanding DX solutions to digitize medical facilities’ overall business processes and enhance performance management and data utilization. - FY2024-H1RestatedAnnual report
「R&D expenses during the interim accounting period were ¥22,774 thousand. There were no material changes in the status of the company’s R&D activities during the interim accounting period.」
There were no material changes in R&D activities, and R&D expenses during the interim accounting period were ¥22,774 thousand. - FY2023First statedAnnual report
「We will continue developing new services and expanding our DX services.」
The company plans to extend DX beyond reservations into general government operations through enhanced existing functions and new service development.